Potential treatment hope for Angelman syndrome supported by a Telethon grant
Life Sciences WA
by Life Sciences WA
5d ago
29/02/24 - The initial development of a novel drug treatment for children living with rare genetic diseases including Angelman syndrome has been supported by a Channel 7 Telethon Trust grant.   World Rare Disease Day is Thursday 29 February 2024.   The research focuses on three imprinting disorders (congenital conditions) associated with faulty genes on chromosome 15: Angelman syndrome (AS), Prader-Willi syndrome (PWS) and 15q11-q13 duplication syndrome (dup15q).   Affected children can experience developmental delays, impaired balance, seizures, difficulty with feeding, swallow ..read more
Visit website
FHRI Fund Enabling Scheme
Life Sciences WA
by Life Sciences WA
5d ago
29/02/24 - The Future Health Research and Innovation (FHRI) Fund Enabling Scheme aims to increase the scale and excellence of health and medical research and innovation in WA by supporting accessible local infrastructure. The FHRI Fund Enabling Scheme will provide support for capital costs associated with undertaking health and medical research and/or innovation in Western Australia. Up to 50 per cent co-funding will be made available for upgrades to laboratory, research and/or innovation facilities in order to provide greater sector access, or better support national or international partners ..read more
Visit website
Emerging Opportunities in Medicinal Cannabis and Psychedelics with Michael Winlo, Emyria Ltd and Fleta Solomon, Little Green Pharma
Life Sciences WA
by Life Sciences WA
1M ago
In this episode of the LSWA podcast, host Tracey Wilkinson interviews Fleta Solomon and Michael Winlo, two experts in the field of psychedelic-assisted therapy and medical cannabis. They discuss the potential of these treatments to revolutionise mental health care and provide a more holistic approach to patient care. The conversation begins with a focus on the use of cannabis to achieve high THC effects for certain patients. Fleta and Mike emphasise the importance of therapy in every treatment plan, whether it be through coaching, encouragement, or support in using medication effectively. They ..read more
Visit website
Pathway to Market: the Role of Clinical Trials with Natalie Barber, Chrysalis Advisory and Peter Richmond, CAHS
Life Sciences WA
by Life Sciences WA
1M ago
In this episode of the LSWA podcast, host Tracey Wilkinson sits down with Natalie Barber, the director of Clinical Operations at Chrysalis Advisory, and Professor Peter Richmond from the University of Western Australia.  Natalie and Peter discuss their respective roles in the clinical trial space. Peter, a paediatrician, focuses on improving children's health by conducting research on vaccines and monoclonal antibodies. He shares his involvement in every stage of the clinical trial process, from vaccine design to regulatory advisory boards. Natalie's role is to support clinician researche ..read more
Visit website
The 5th Annual Western Australian BioInnovation Symposium
Life Sciences WA
by Life Sciences WA
1M ago
You are invited to attend the 5th Annual Western Australian BioInnovation Symposium to be held in Perth on 22-23 February 2024. The WA BioInnovation Symposium is a premier event in Western Australia that showcases the latest and greatest in life sciences innovations. The symposium serves as a convergence point for innovators, industry partners, and investors, offering a unique opportunity to explore partnering opportunities in life science sectors. The symposium will build on the outstanding program of previous years and for the first year, have a broader life sciences focus, such as agbi ..read more
Visit website
Engaging with Academics and Tech Transfer Offices - Simon Handford, TTO and Angela Fonceca, Academic
Life Sciences WA
by Life Sciences WA
3M ago
In this episode of LSWA Investor Meets Innovator, Host Tracey Wilkinson talks with Simon Handford and Angela Fonceca about the challenges and complexities of tech transfer offices and taking research to commercialisation. They discuss the challenges of taking an innovation from academia and industry, the slow pace of negotiations, issues with funding commitments from industry partners, and the role of technology transfer offices in aiding researchers. They talk about the importance of managing expectations with various stakeholders and balancing academic records with commercialisation efforts ..read more
Visit website
Engaging with Founding Inventors: Ian Brown & Intan Oldakowska - Rex Ortho
Life Sciences WA
by Life Sciences WA
3M ago
In this episode of the Investor Meets Innovator Podcast, host Peter Birch is joined by Ian Brown, Executive Chairman, and Intan Oldakowska, Chief Scientific Officer, of Rex Ortho. They discuss the journey of Rex Ortho, a platform technology company focused on orthopaedic fixations, particularly in proximal femoral fractures. Intan shares the background of Rex Ortho, which started in 2012 when she and her co-founder, Matt Oldakowski, were approached by a surgeon with a need for a solution to fixation failures. Intan and Matt embarked on their PhD research, learning about biomechanical engineeri ..read more
Visit website
Investing with Impact in the Life Sciences Dr Melissa McBurnie - Brandon Capital
Life Sciences WA
by Life Sciences WA
3M ago
In this episode of the Investor Meets Innovator Podcast, host Peter Birch sits down with Dr Melissa McBurnie, Partner and Head of Impact at Brandon Capital. You will hear about how Brandon Capital approaches investing with impact in the life sciences and get some insights into the processes that they use when making an investment in this space. You will also learn about the role balancing financial returns plays in creating positive impact. Links & Resources: AusBiotech MTPConnect Life Sciences WA Brandon Capital Partners Brandon BioCatalyst Brandon Capital on LinkedIn We’d love your feed ..read more
Visit website
More positive news for neuroprotective drug ARG-007
Life Sciences WA
by Life Sciences WA
3M ago
23/11/23 - A Western Australian developed potential therapy ARG-007, designed to reduce brain tissue death after brain injury and other neurological conditions, has been granted Orphan Drug Designation status by the U.S. Food and Drug Administration for treatment of Hypoxic Ischaemic Encephalopathy (HIE). HIE, a form of brain injury caused by babies being deprived of oxygen before, during or immediately after birth, contributes to one of the leading causes of death and disability in children under two. In an ASX announcement, Argenica Therapeutics, the WA biotech company working towards commer ..read more
Visit website
Life Sciences WA Appoints CEO
Life Sciences WA
by Life Sciences WA
4M ago
13/11/23 - It is with tremendous pleasure that Life Sciences WA announces the appointment of Dr Tobias Schoep as its new CEO. This newly created position reflects the growth of Life Sciences WA and the commitment to achieving the organisation’s goal of connecting, accelerating and promoting Life Sciences innovation in Western Australia. Tobias brings a wealth of experience in the biotechnology, academic and business domains working across health sciences and agriculture. Tobias’ previous roles include research positions with the Telethon Kids Institute, UC Santa Barbara, Ondek, and Rumen Biote ..read more
Visit website

Follow Life Sciences WA on FeedSpot

Continue with Google
Continue with Apple
OR